IMMIX BIOPHARMA INC.
1.5750
05-11月-24 15:54:47
15 分の遅延
株式
-0.0050
-0.32%
本日の幅
1.4800 - 1.5800
ISIN
N/A
ソース
NASDAQ
-
02 10 2024 09:32:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
28 8 2024 09:32:00 提供 Nasdaq GlobeNewswire
-
25 7 2024 21:31:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
08 7 2024 09:31:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
17 6 2024 09:35:00 提供 Nasdaq GlobeNewswire
-
10 5 2024 09:35:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29 4 2024 09:39:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 4 2024 09:32:00 提供 Nasdaq GlobeNewswire
-
20 3 2024 09:46:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05 3 2024 09:35:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma 12 Month Review Progress Update
21 2 2024 09:31:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 2 2024 16:45:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
07 2 2024 09:37:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 2 2024 22:30:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 2 2024 15:20:11 提供 Nasdaq GlobeNewswire
-
24 1 2024 08:35:00 提供 Nasdaq GlobeNewswire
- <<
- <
- 1
- >